Form 3 - Initial statement of beneficial ownership of securities:
SEC Accession No. 0000950170-23-030487
Filing Date
2023-06-28
Accepted
2023-06-28 18:59:32
Documents
2
Period of Report
2023-06-20

Document Format Files

Seq Description Document Type Size
1 3 ownership.html 3  
1 3 ownership.xml 3 1683
2 EX-24 cere-ex24.htm EX-24 26874
  Complete submission text file 0000950170-23-030487.txt   30050
Mailing Address C/O TRANSLATE BIO, INC. 29 HARTWELL AVENUE LEXINGTON MA 02421
Business Address
Burgess Paul D. (Reporting) CIK: 0001744627 (see all company filings)

Type: 3 | Act: 34 | File No.: 001-39311 | Film No.: 231053836

Mailing Address 222 JACOBS STREET SUITE 200 CAMBRIDGE MA 02141
Business Address 222 JACOBS STREET SUITE 200 CAMBRIDGE MA 02141 844-304-2048
Cerevel Therapeutics Holdings, Inc. (Issuer) CIK: 0001805387 (see all company filings)

EIN.: 000000000 | State of Incorp.: DE | Fiscal Year End: 1231
SIC: 2834 Pharmaceutical Preparations